## David T. Curiel, M.D.

Director University of Alabama at Birmingham Gene Therapy Center 1824 Sixth Avenue South Room WTI 620 Birmingham, AL 35294 United States



1974-1978	B.A. Chemistry, West Georgia College, Carrollton, GA
1978-1982	M.D., Emory University School of Medicine, Atlanta, GA
1982-1983	Internship – Medicine, Emory University, Affiliated Hospitals, Atlanta, GA
1983-1985	Residency – Medicine, Emory University, Affiliated Hospitals
1985-1989	Pulmonary Medicine, Pulmonary Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD
1989-1990	Biotechnology, Navy Medical Oncology Branch, National Cancer Institute, NIH, Bethesda, MD
1990-1991	Visiting Assistant Professor of Medicine, Division of Pulmonary Diseases, Department of Medicine, The
	University of North Carolina, Chapel Hill, NC
1991-1993	Assistant Professor of Medicine, Division of Pulmonary Diseases, Department of Medicine, The University of
1002 1002	North Carolina
1992-1993 1992-1993	Curriculum in Genetics, The University of North Carolina Member, Lineberger Comprehensive Cancer Center, The
1993-1996	University of North Carolina Associate Professor, Department of Medicine, Division of
1993-1990	Pulmonary and Critical Care Medicine and Microbiology,
	The University of Alabama at Birmingham, Birmingham, AL
1995-1996	Associate Professor of Pathology and Gynecologic
	Oncology, Arthritis and Musculoskeletal Diseases Center,
	The University of Alabama at Birmingham
1996-1996	Associate Professor, Division of Hematology/Oncology,
	The University of Alabama at Birmingham
1993-1999	Director, Gene Therapy Program, The University of Alabama at Birmingham
1996-present	Professor, Departments of Medicine, Gynecologic Oncology, Pathology and Hematology/Oncology, Senior
	Scientist, Comprehensive Cancer Center, Center for AIDS Research, Arthritis and Musculoskeletal Diseases Center
	and Gregory Fleming Cystic Fibrosis Center, The University of Alabama at Birmingham
1997-present	Jeanne and Ann Griffin Chair for Women's Cancer
	Research, The University of Alabama at Birmingham
1998-present	Professor, Biomedical Engineering, University of Alabama at Birmingham
1999-present	Director, Gene Therapy Center, The University of Alabama at Birmingham
Honors	
1992-1993	James W. Woods Junior Faculty Award, University of
	North Carolina School of Medicine
1993-1993	Visiting Professor, Department of Clinical Oncology, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK
1996	American Lung Association Career Investigator Award
1997	Southern Section – American Federation of Medical Research Young Investigator Award
1998-present	International Society of Cancer Gene Therapy, Vice President

## CAR-Independent Gene Transfer to Accomplish Efficient and Specific Genetic Modification of Target Cells Via Adenoviral Vectors

Adenoviruses have been widely employed for a variety of gene therapy applications, owing largely to their unparalleled efficiency in accomplishing in vivo gene transfer. Despite this unique capacity, full use of these vectors for gene therapy applications has been limited by their reliance on target cell entry via the native adenovirus receptor, CAR. On this basis, target cells which express low amounts of CAR are relatively resistant to adenoviral vectors (Ad). Alternatively, recognition of CAR may allow gene transfer via Ad to ectopic target cell sites with attendant toxic/morbid consequences. Thus, the ability to direct adenovirus to cell-specific receptors, in a CAR-independent manner, would potentially allow circumvention of these two key limitations of Ad vectors. To this end, we have endeavored tropism-modifications of Ad to allow cell-specific gene delivery. This has been achieved via heterologous retargeting complexes and via genetic modification of the Ad capsid. Both of these strategies have allowed the achievement of CAR-independent gene delivery to target cells. Further, such CAR-independent gene delivery has allowed the achievement of both cell-specific gene delivery as well as gene transfer efficiency augmentations. On this basis, it is clear that strategies to alter Ad tropism may allow greatly improved utilities of Ad for gene therapy applications.